報價延遲最少15分鐘:2025/06/17 17:50 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.27 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-46.00/-0.07
|
|
企業價值
10.13M
|
| 資產負債 |
|
每股賬面淨值
0.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/17 17:50 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection. |